
What Sen. Sullivan Told Us About the Alaska Ballot Scandal
Reporting on market developments concerning What Sen. Sullivan Told Us About the Alaska Ballot Scandal. Industry analysts and investors are monitoring the operational, strategic, a...
Query our full-text historical index across market dispatches, earnings reports, central bank policies, and financial analyses.

Reporting on market developments concerning What Sen. Sullivan Told Us About the Alaska Ballot Scandal. Industry analysts and investors are monitoring the operational, strategic, a...

Reporting on market developments concerning What We Know About the Alaska Election Controversy. Industry analysts and investors are monitoring the operational, strategic, and finan...

Reporting on market developments concerning Just About Every Part of Building a House Is Getting More Expensive. Industry analysts and investors are monitoring the operational, str...

Extended trading revealed sharp cross-sector divergence as investors parsed fresh updates from Starbucks, Reddit, Pinterest, and Intel.

Alphabet has lost approximately $500 billion in market value as Wall Street scrutinizes mounting artificial intelligence expenditures and escalating antitrust headwinds.

Alphabet shares faced renewed selling pressure as investors parsed mounting infrastructure expenditures and ongoing regulatory headwinds in digital advertising.

Memory chipmakers are taking a page from Big Oil's capital discipline playbook as surging AI demand tests the semiconductor sector's historic cyclicality.

As the Federal Reserve weighs prolonged higher interest rates, Wall Street questions whether monetary policy can truly dampen massive corporate spending on artificial intelligence.

Public ethics disclosures reveal top administration officials hold equities across over 40 major corporations, spanning energy, defense, and technology sectors.

Wall Street sharpens its scrutiny as Microsoft and Alphabet deliver earnings results that test investor patience over massive AI infrastructure investments.

Boston Scientific shares slid as softer-than-expected sales momentum raised questions about hospital procedural volumes and medtech demand.

Prediction platforms and swap markets show shifting probabilities as stubborn inflation data fuels debate over the Federal Reserve's next policy trajectory.